ALNYLAM PHARMACEUTICALS, INC. Increase (Decrease) in Inventories
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Increase (Decrease) in Inventories of $3.04 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInventories · last filed 2026-07-30
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in inventories for the quarter ending 2025-12-31 was $13.86M.
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in inventories for the quarter ending 2025-09-30 was -$4.98M.
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in inventories for the quarter ending 2025-06-30 was -$11.14M.
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in inventories for the quarter ending 2025-03-31 was -$6.21M.
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in inventories for fiscal 2025 was -$8.47M.
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in inventories for fiscal 2024 was -$13.59M.
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in inventories for fiscal 2023 was -$18.37M, a 153.81% decline from fiscal 2022.
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in inventories for fiscal 2022 was $34.14M, a 29.23% increase from fiscal 2021.
| Period end | Increase (Decrease) in Inventories 3 month | Increase (Decrease) in Inventories 6 month | Increase (Decrease) in Inventories 9 month | Increase (Decrease) in Inventories 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.04M 10-Q · filed 2026-07-30 | |||
| 2025-12-31 | $13.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $8.88M derived: sum of 2 quarters · filed 2026-02-12 | -$2.26M derived: sum of 3 quarters · filed 2026-07-30 | -$8.47M 10-K · filed 2026-02-12 |
| 2025-09-30 | -$4.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$16.12M derived: sum of 2 quarters · filed 2026-07-30 | -$22.34M 10-Q · filed 2025-10-30 | -$23.18M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | -$11.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$17.36M 10-Q · filed 2026-07-30 | -$18.21M derived: sum of 3 quarters · filed 2026-07-30 | -$24.13M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | -$6.21M 10-Q · filed 2025-05-01 | -$7.06M derived: sum of 2 quarters · filed 2026-02-12 | -$12.99M derived: sum of 3 quarters · filed 2026-02-12 | -$19.78M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-12-31 | -$849.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | -$6.77M derived: sum of 2 quarters · filed 2026-02-12 | -$13.57M derived: sum of 3 quarters · filed 2026-02-12 | -$13.59M 10-K · filed 2026-02-12 |
| 2024-09-30 | -$5.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$12.72M derived: sum of 2 quarters · filed 2025-10-30 | -$12.74M 10-Q · filed 2025-10-30 | -$24.73M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-06-30 | -$6.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | -$6.82M 10-Q · filed 2025-07-31 | -$18.81M derived: sum of 3 quarters · filed 2026-02-12 | -$23.60M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-03-31 | -$22.00K 10-Q · filed 2025-05-01 | -$12.01M derived: sum of 2 quarters · filed 2026-02-12 | -$16.81M derived: sum of 3 quarters · filed 2026-02-12 | -$18.79M derived: sum of 4 quarters · filed 2026-02-12 |
| 2023-12-31 | -$11.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | -$16.79M derived: sum of 2 quarters · filed 2026-02-12 | -$18.77M derived: sum of 3 quarters · filed 2026-02-12 | -$18.37M 10-K · filed 2026-02-12 |
| 2023-09-30 | -$4.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | -$6.78M derived: sum of 2 quarters · filed 2024-10-31 | -$6.38M 10-Q · filed 2024-10-31 | $12.60M derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-06-30 | -$1.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$1.58M 10-Q · filed 2024-08-01 | $17.40M derived: sum of 3 quarters · filed 2025-02-13 | $25.28M derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-03-31 | $403.00K 10-Q · filed 2024-05-02 | $19.38M derived: sum of 2 quarters · filed 2025-02-13 | $27.27M derived: sum of 3 quarters · filed 2025-02-13 | $36.47M derived: sum of 4 quarters · filed 2025-02-13 |
| 2022-12-31 | $18.98M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $26.86M derived: sum of 2 quarters · filed 2025-02-13 | $36.06M derived: sum of 3 quarters · filed 2025-02-13 | $34.14M 10-K · filed 2025-02-13 |
| 2022-09-30 | $7.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $17.08M derived: sum of 2 quarters · filed 2023-11-02 | $15.16M 10-Q · filed 2023-11-02 | $25.92M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $9.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $7.27M 10-Q · filed 2023-08-03 | $18.03M derived: sum of 3 quarters · filed 2024-02-15 | $31.67M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | -$1.93M 10-Q · filed 2023-05-04 | $8.83M derived: sum of 2 quarters · filed 2024-02-15 | $22.47M derived: sum of 3 quarters · filed 2024-02-15 | $26.42M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | $10.76M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $24.39M derived: sum of 2 quarters · filed 2024-02-15 | $28.35M derived: sum of 3 quarters · filed 2024-02-15 | $26.41M 10-K · filed 2024-02-15 |
| 2021-09-30 | $13.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | $17.59M derived: sum of 2 quarters · filed 2022-10-27 | $15.65M 10-Q · filed 2022-10-27 | $24.12M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $3.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-28 | $2.02M 10-Q · filed 2022-07-28 | $10.48M derived: sum of 3 quarters · filed 2023-02-23 | $13.27M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | -$1.93M 10-Q · filed 2022-04-28 | $6.53M derived: sum of 2 quarters · filed 2023-02-23 | $9.31M derived: sum of 3 quarters · filed 2023-02-23 | $21.54M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $8.46M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $11.25M derived: sum of 2 quarters · filed 2023-02-23 | $23.47M derived: sum of 3 quarters · filed 2023-02-23 | $35.43M 10-K · filed 2023-02-23 |
| 2020-09-30 | $2.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | $15.01M derived: sum of 2 quarters · filed 2021-10-28 | $26.96M 10-Q · filed 2021-10-28 | $31.28M derived: sum of 4 quarters · filed 2022-02-10 |
| 2020-06-30 | $12.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $24.18M 10-Q · filed 2021-08-03 | $28.49M derived: sum of 3 quarters · filed 2022-02-10 | $41.55M derived: sum of 4 quarters · filed 2022-02-10 |
| 2020-03-31 | $11.95M 10-Q · filed 2021-04-29 | $16.27M derived: sum of 2 quarters · filed 2022-02-10 | $29.32M derived: sum of 3 quarters · filed 2022-02-10 | $37.23M derived: sum of 4 quarters · filed 2022-02-10 |
| 2019-12-31 | $4.32M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-10 | $17.37M derived: sum of 2 quarters · filed 2022-02-10 | $25.28M derived: sum of 3 quarters · filed 2022-02-10 | $32.41M 10-K · filed 2022-02-10 |
| 2019-09-30 | $13.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $20.96M derived: sum of 2 quarters · filed 2020-11-05 | $28.09M 10-Q · filed 2020-11-05 | $40.39M derived: sum of 4 quarters · filed 2021-02-11 |
| 2019-06-30 | $7.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $15.04M 10-Q · filed 2020-08-06 | $27.33M derived: sum of 3 quarters · filed 2021-02-11 | |
| 2019-03-31 | $7.13M 10-Q · filed 2020-05-06 | $19.43M derived: sum of 2 quarters · filed 2021-02-11 | ||
| 2018-12-31 | $12.29M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $22.64M 10-K · filed 2021-02-11 | ||
| 2018-09-30 | $10.35M 10-Q · filed 2019-10-31 | |||
| 2017-12-31 | $0.00 10-K · filed 2020-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |